

Special Emphasis Panel. Member Conflict SEP.

Date: February 26, 2021.

Time: 10:00 a.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute of Child Health and Human Development, 6710B Rockledge Drive, Bethesda, MD 20892 (Video-Assisted Meeting).

Contact Person: Helen Huang, Ph.D. Scientific Review Officer Scientific Review Branch Eunice, Kennedy Shriver National Institute of Child Health and Human Development, NIH Bethesda, MD 20817 301-435-8207 helen.huang@nih.gov

Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel; Maternal and Pediatric Precision in Therapeutics Hub (P50)

Date: March 9–10, 2021.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute of Child Health and Human Development, 6710B Rockledge Drive, Bethesda, MD 20817 (Video-Assisted Meeting)

Contact Person: Christiane M. Robbins, Scientific Review Officer Scientific Review Branch, (SRB), DER Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, DHHS 6710B Rockledge Drive, Rm 2121A Bethesda, MD 20817 301-451-4989 crobbins@mail.nih.gov

Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel, Maternal and Pediatric Precision in Therapeutics Hub (P30)

Date: March 11, 2021.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute of Child Health and Human Development, 6710B Rockledge Drive, Bethesda, MD 20817 (Video-Assisted Meeting)

Contact Person: Christiane M. Robbins Scientific Review Officer Scientific Review Branch (SRB), DER Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, DHHS 6710B Rockledge Drive, Rm 2121A Bethesda, MD 20817 301-451-4989 crobbins@mail.nih.gov

(Catalogue of Federal Domestic Assistance Program Nos. 93.865, Research for Mothers and Children, National Institutes of Health, HHS)

Dated: January 12, 2021.

Ronald J. Livingston, Jr.,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2021-00924 Filed 1-14-21; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Review of Dietary Biomarker Development Centers (U2C).

Date: February 17–18, 2021.

Time: 9:00 a.m. to 12:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Video Meeting).

Contact Person: Lan Tian, Ph.D., Scientific Review Officer, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 6707 Democracy Boulevard, Room 7349, Bethesda, MD 20892-5452, (301) 496-7050, email: tianl@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: January 12, 2021.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2021-00920 Filed 1-14-21; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Alcohol Abuse and Alcoholism; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Advisory Council on Alcohol Abuse and Alcoholism, February 4, 2021, 11:00

a.m. to February 4, 2021, 5:00 p.m., National Institutes of Health, National Institute on Drug Abuse, 6700B Rockledge Drive, Bethesda, MD, 20892 which was published in the **Federal Register** on December 21, 2020, 85 FR 83101.

This notice is being amended to change the end time of the closed session as well as the start time and end time of the open session of the meeting. The closed session will now be held from 11:00 a.m. to 12:00 p.m. and the open session will now be held from 12:00 p.m. to 5:30 p.m. The meeting is partially closed to the public.

Dated: January 12, 2021.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2021-00921 Filed 1-14-21; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development.

FOR FURTHER INFORMATION CONTACT:

Licensing information may be obtained by communicating with Vidita Choudhry, Ph.D., Office of Technology Transfer and Development, National Heart, Lung, and Blood Institute, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 301-594-4095; email: vidita.choudhry@nih.gov. A signed Confidential Disclosure Agreement may be required to receive any unpublished information.

SUPPLEMENTARY INFORMATION:

Technology description follows.

High-Throughput COVID-19 Diagnostic Test That Detects Both Viral and Host Nucleic Acid

The virus that causes COVID-19 is designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The rapid worldwide spread and impact of COVID-19 has created a need for accurate, reliable, and readily accessible testing on a massive scale. The subject invention describes development of a